
Gland Pharma Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Indicators
2026-05-06 08:06:14Gland Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance on weekly charts, despite a recent 2.43% decline in its share price. This nuanced change is underscored by a complex interplay of technical indicators, reflecting both optimism and caution among investors in the pharmaceuticals and biotechnology sector.
Read full news article
Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-05-05 08:07:29Gland Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. This transition comes amid a strong price performance that outpaces the broader Sensex, signalling renewed investor interest in the pharmaceuticals and biotechnology sector.
Read full news article
Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-05-04 08:02:31Gland Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite this, key indicators such as the MACD and KST suggest a nuanced outlook, with weekly signals showing mild bullishness contrasting with monthly bearish tendencies. This complex technical landscape warrants close attention from investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
Gland Pharma Ltd is Rated Hold
2026-05-02 10:10:25Gland Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 Mar 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 02 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.
Read full news article
Gland Pharma Ltd Technical Momentum Shifts to Sideways; Hold Rating Upgraded
2026-04-28 08:06:01Gland Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more neutral sideways trend, reflecting a cautious optimism among investors. The stock’s recent 3.44% gain to ₹1,773.30, coupled with mixed signals from key technical indicators such as MACD, RSI, and moving averages, suggests a complex interplay of bullish and bearish forces shaping its near-term trajectory.
Read full news article
Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-04-27 08:02:44Gland Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of late April 2026. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s mixed technical indicators and price action suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
Gland Pharma Ltd is Rated Hold
2026-04-21 10:10:33Gland Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-04-21 08:06:12Gland Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest day decline of 0.50%, the stock’s recent performance and technical signals suggest a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.
Read full news article
Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-04-17 08:04:08Gland Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of April 2026. Despite a recent downgrade in technical trend, the stock’s fundamental performance and mixed indicator signals suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news articleClarification With Respect To The Announcement Made On 13Th April 2026 Regarding Postal Ballot Notice
27-Apr-2026 | Source : BSEClarification with respect to the Announcement made on 13th April 2026 regarding Postal Ballot Notice
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Financial Year Ended March 31 2026 And To Consider And Recommend Payment Of Final Dividend If Any For The Financial Year Ended March 31 2026
21-Apr-2026 | Source : BSEGland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 inter alia to consider and approve Audited Financial Results for the Quarter and financial year ended March 31 2026 and to consider and recommend payment of Final Dividend if any for the financial year ended March 31 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
21-Apr-2026 | Source : BSEQ4FY26 Earnings Call Intimation
Corporate Actions
15 May 2026
Gland Pharma Ltd has declared 1800% dividend, ex-date: 14 Aug 25
No Splits history available
No Bonus history available
No Rights history available






